Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus

A. Szegedi, E. Simics, M. Aleksza, I. Horkay, K. Gaál, S. Sipka, J. Hunyadi, E. Kiss

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objective. Ultraviolet-A1 (UVA1) phototherapy is effective for a variety of dermatological diseases. We examined the effectiveness and reliability of low-dose UVA1 phototherapy (60kJ/m2/treatment) in patients suffering from systemic lupus erythematosus (SLE). We studied the changes in immunological parameters. Methods. The patients received a 9-week course of phototherapy according to the following regimen: five times a week during the first 3 weeks, three times a week during the second 3 weeks and twice during the last 3 weeks. Among other things, we analysed the proportions of T helper 1 (Th1), Th2, T cytotoxic (Tc1) and Tc2 cell populations in the peripheral blood of patients by flow cytometric detection of intracytoplasmic interferonγ (IFN-γ) and interleukin 4 (IL-4). Results. Our study showed the improvement of clinical symptoms determined by the subjective clinical disease activity scoring and the SLE Disease Activity Index (SLEDAI). By the end of UVA1 phototherapy, the mean value of SLEDAI had decreased from 7.2±5.6 to 0.9±1.8, which was significant (P = 0.005). Immunological investigations detected a decrease in the frequency of IFN-γ-producing Th1 and Tc1 cells and a decrease in the Th1/Th2 and Tc1/Tc2 ratios after UVA1 therapy. Conclusion. According to the literature, IFN-γ has a pathogenic role in the development of SLE. We observed a decreased proportion of IFN-γ-secreting cells, which we think is presumably one of the beneficial effects of UVA1 therapy. On the basis of our study, UVA1 phototherapy does seem to be an effective adjuvant in the treatment of SLE patients.

Original languageEnglish
Pages (from-to)925-931
Number of pages7
JournalRheumatology
Volume44
Issue number7
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Phototherapy
Systemic Lupus Erythematosus
Interferons
Ultraviolet Therapy
Th1 Cells
Interleukin-4
Therapeutics
Population

Keywords

  • IFN-γ
  • Phototherapy
  • Systemic lupus erythematosus
  • Th1
  • Th2

ASJC Scopus subject areas

  • Neuroscience(all)
  • Rheumatology

Cite this

Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus. / Szegedi, A.; Simics, E.; Aleksza, M.; Horkay, I.; Gaál, K.; Sipka, S.; Hunyadi, J.; Kiss, E.

In: Rheumatology, Vol. 44, No. 7, 07.2005, p. 925-931.

Research output: Contribution to journalArticle

@article{0ad0bd0504ff4674997452de5cb516d2,
title = "Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus",
abstract = "Objective. Ultraviolet-A1 (UVA1) phototherapy is effective for a variety of dermatological diseases. We examined the effectiveness and reliability of low-dose UVA1 phototherapy (60kJ/m2/treatment) in patients suffering from systemic lupus erythematosus (SLE). We studied the changes in immunological parameters. Methods. The patients received a 9-week course of phototherapy according to the following regimen: five times a week during the first 3 weeks, three times a week during the second 3 weeks and twice during the last 3 weeks. Among other things, we analysed the proportions of T helper 1 (Th1), Th2, T cytotoxic (Tc1) and Tc2 cell populations in the peripheral blood of patients by flow cytometric detection of intracytoplasmic interferonγ (IFN-γ) and interleukin 4 (IL-4). Results. Our study showed the improvement of clinical symptoms determined by the subjective clinical disease activity scoring and the SLE Disease Activity Index (SLEDAI). By the end of UVA1 phototherapy, the mean value of SLEDAI had decreased from 7.2±5.6 to 0.9±1.8, which was significant (P = 0.005). Immunological investigations detected a decrease in the frequency of IFN-γ-producing Th1 and Tc1 cells and a decrease in the Th1/Th2 and Tc1/Tc2 ratios after UVA1 therapy. Conclusion. According to the literature, IFN-γ has a pathogenic role in the development of SLE. We observed a decreased proportion of IFN-γ-secreting cells, which we think is presumably one of the beneficial effects of UVA1 therapy. On the basis of our study, UVA1 phototherapy does seem to be an effective adjuvant in the treatment of SLE patients.",
keywords = "IFN-γ, Phototherapy, Systemic lupus erythematosus, Th1, Th2",
author = "A. Szegedi and E. Simics and M. Aleksza and I. Horkay and K. Ga{\'a}l and S. Sipka and J. Hunyadi and E. Kiss",
year = "2005",
month = "7",
doi = "10.1093/rheumatology/keh643",
language = "English",
volume = "44",
pages = "925--931",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus

AU - Szegedi, A.

AU - Simics, E.

AU - Aleksza, M.

AU - Horkay, I.

AU - Gaál, K.

AU - Sipka, S.

AU - Hunyadi, J.

AU - Kiss, E.

PY - 2005/7

Y1 - 2005/7

N2 - Objective. Ultraviolet-A1 (UVA1) phototherapy is effective for a variety of dermatological diseases. We examined the effectiveness and reliability of low-dose UVA1 phototherapy (60kJ/m2/treatment) in patients suffering from systemic lupus erythematosus (SLE). We studied the changes in immunological parameters. Methods. The patients received a 9-week course of phototherapy according to the following regimen: five times a week during the first 3 weeks, three times a week during the second 3 weeks and twice during the last 3 weeks. Among other things, we analysed the proportions of T helper 1 (Th1), Th2, T cytotoxic (Tc1) and Tc2 cell populations in the peripheral blood of patients by flow cytometric detection of intracytoplasmic interferonγ (IFN-γ) and interleukin 4 (IL-4). Results. Our study showed the improvement of clinical symptoms determined by the subjective clinical disease activity scoring and the SLE Disease Activity Index (SLEDAI). By the end of UVA1 phototherapy, the mean value of SLEDAI had decreased from 7.2±5.6 to 0.9±1.8, which was significant (P = 0.005). Immunological investigations detected a decrease in the frequency of IFN-γ-producing Th1 and Tc1 cells and a decrease in the Th1/Th2 and Tc1/Tc2 ratios after UVA1 therapy. Conclusion. According to the literature, IFN-γ has a pathogenic role in the development of SLE. We observed a decreased proportion of IFN-γ-secreting cells, which we think is presumably one of the beneficial effects of UVA1 therapy. On the basis of our study, UVA1 phototherapy does seem to be an effective adjuvant in the treatment of SLE patients.

AB - Objective. Ultraviolet-A1 (UVA1) phototherapy is effective for a variety of dermatological diseases. We examined the effectiveness and reliability of low-dose UVA1 phototherapy (60kJ/m2/treatment) in patients suffering from systemic lupus erythematosus (SLE). We studied the changes in immunological parameters. Methods. The patients received a 9-week course of phototherapy according to the following regimen: five times a week during the first 3 weeks, three times a week during the second 3 weeks and twice during the last 3 weeks. Among other things, we analysed the proportions of T helper 1 (Th1), Th2, T cytotoxic (Tc1) and Tc2 cell populations in the peripheral blood of patients by flow cytometric detection of intracytoplasmic interferonγ (IFN-γ) and interleukin 4 (IL-4). Results. Our study showed the improvement of clinical symptoms determined by the subjective clinical disease activity scoring and the SLE Disease Activity Index (SLEDAI). By the end of UVA1 phototherapy, the mean value of SLEDAI had decreased from 7.2±5.6 to 0.9±1.8, which was significant (P = 0.005). Immunological investigations detected a decrease in the frequency of IFN-γ-producing Th1 and Tc1 cells and a decrease in the Th1/Th2 and Tc1/Tc2 ratios after UVA1 therapy. Conclusion. According to the literature, IFN-γ has a pathogenic role in the development of SLE. We observed a decreased proportion of IFN-γ-secreting cells, which we think is presumably one of the beneficial effects of UVA1 therapy. On the basis of our study, UVA1 phototherapy does seem to be an effective adjuvant in the treatment of SLE patients.

KW - IFN-γ

KW - Phototherapy

KW - Systemic lupus erythematosus

KW - Th1

KW - Th2

UR - http://www.scopus.com/inward/record.url?scp=22844437671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22844437671&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keh643

DO - 10.1093/rheumatology/keh643

M3 - Article

C2 - 15827034

AN - SCOPUS:22844437671

VL - 44

SP - 925

EP - 931

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 7

ER -